According to the most recent annual report, Enzolytics Inc. owns 49% of a company doing business in Europe: The European entity in Europe is currently conducting clinical trials, and has also filed for a mass use permit. Entering text into the input field will update the search result below. I wrote this article myself, and it expresses my own opinions. The coronavirus has structure correlative to that of the HIV virus. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. Prior to his current position as CEO and Board Chairman of Enzolytics, Mr. Cotropia served as CEO of BioClonetics Immunotherapeutics, Inc. from its formation in 2009 until the recent acquisition of BioClonetics by Enzolytics. Plano, TX.,April 16, 2020/-- Enzolytics- (OTC Pink Sheet-ENZC) is pleased to update shareholders on the current corporate initiatives. Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article. Immuno Technologies, Inc. is a US-based company that focuses on applied research for infectious diseases. exchange agreement, all the liabilities of Immunotech Laboratories, Inc. were assumed by Enzolytics Solutions, Inc. On June 22, 2017, Eco Petroleum Solutions, Inc.(OTC Markets "ECPO" or the "Company") a nnounces that IMMB BG, a subsidiary of Immunotech Laboratories, Inc., the Company's subsidiary, has issued an According to data from Fintel, the short borrow fee rate currently stands at 3.78%. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Looking up information on h, Active, which can be bought in Bulgaria for around, This dietary supplement is being distributed by. Software Test Analyst Internship. Identify a CMO, Contract Manufacturing Organization, to produce the validation batch for Immunotech Laboratories BG-Europe. Charles Cotropia, CEO of BioClonetics added, "Our proprietary methodology may also be applied to produce monoclonal antibodies against other infectious diseases and the invitation by the National Science Foundation (NSF) to apply for funding to further BioClonetics efforts to develop an anti-SARS-Cov-2 monoclonal antibodies using our proprietary technology is an exciting development for BioClonetics. Enzolytics is seeking a Contract Manufacturing Organization (CMO) in the United States to produce the Immunotherapy Treatment to be used as the validation batch in coordination with the Bulgarian regulatory authority and Immunotech BG-Europe. Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified (as recently in his keynote address at the AIDS International Conference) that a success in treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms. Please. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application. He is licensed to practice law in Federal District and Texas State courts and before the United States Patent and Trademark Office. didnt report any revenues in the first nine months of 2020. barely had any cash reserves as of September and its shareholders equity and working capital positions were negative. Provide the planning and leadership to the Development Department by ensuring that the appropriate structures, systems, competencies and values are developed in order to meet and exceed the goals of the Marketing plan. IPF has been shown to not be subject to viral resistance and is cost effective. I wrote this article myself, and it expresses my own opinions. Moreover, the Company has proprietary methodology needed to produce anti-coronavirus monoclonal antibodies targeting such sites. The factory is estimated to be operational no later than 30.06.2021. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. currently moving forward to produce monoclonal antibodies targeting COVID-19. COLLEGE STATION, TX / ACCESSWIRE / May 16, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) ( ). Its also unclear if the Series B shares that the owners of the latter received gave them control of Enzolytics. Phone: (972)292-9414
9,000,000 servings sold per month. The company has made updates to its corporate website , www.enzolytics.com, and will continue to do so to provide further information to our shareholders. ImmunoTech Laboratories BG-Europe has filed for a mass use permit, Phase IV, in Bulgaria. If the dividend or share buyback yield is high - even better. I have no preference for sectors or countries - I'm as comfortable owning a part of a cement miner in Peru as holding shares in a wheat farming firm in Bulgaria. 2000 North Central Expressway, Suite 104 Plano, TX 75074 (972)-292-9414 www.enzolytics.com
[email protected] SIC Code 541711 Annual Report For the Period Ending: December 31, 2021 (the "Reporting Period") As of December the number of shares outstanding of our Common Stock was: outstanding of our Common Stock was: 2,797,935,953. On YouTube, Enzolytics is covered by several channels such as Moon Market, The Laptop Legend, Insider Financial, and Capital Consultant. Dr. Cotropia holds a Medicine Degree from the Univ. transformation acquisition of BioClonetics, is focused on developing fully human monoclonal antibodies targeting. Enzolytics has a valuation of $982.1 million but I dont think the business is worth much in its current state. Perform your own due diligence and consult a financial professional before trading. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. Therefore, there will always be the need for effective monoclonal antibodies. Dr. Cotropia has worked previously at the M.D. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. I don't think the previous auditor had the PCAOB designation. The company recently merged with BioClonetics and plans to develop treatments for HIV and COVID-19. Prior to co-founding BioCLonetics, Mr. Cotropia served as a partner and senior counsel at Sidley Austin LLP. * $ONFO +76% at market open pic.twitter.com/gOLBZjlqJ2, Commonstock (@JoinCommonstock) May 26, 2023. and it looks like the drugs are in an early phase of development, so I doubt this business should be worth much at the current time. It recently merged with another biotechnology company, which aims to treat HIV and COVID-19, but there is little information on the matter. The current market capitalization is larger than $600 million. If it's a value stock - great. Taking into account this fact, the announcement is positive: Enzolytics, Inc. today, announced it has accepted a proposal from a Houston based PCAOB Audit firm to Audit the Company's year-end financial statements, subject to the receipt and acceptance of the engagement letter. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications. I have no business relationship with any company whose stock is mentioned in this article. Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. In my opinion, investors need to remain. They represent more than 60% of the total amount of assets. - Create and execute test cases (API & UI) - Identify and reports bug. $ONFO #Ai have you seen this stock? I put in a search for "dogs" and african animals came up. PLANO, TX/ ACCESSWIRE/ April 16, 2020/ Enzolytics- is pleased to update shareholders on the current corporate initiatives. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Every few minutes, theres a new tweet with the $ENZC hashtag as well as a new post on Stocktwits. $onfo in news and float are lit pic.twitter.com/Q8eIveRfgd. It is free from major neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. According to the company, in vitro testing has shown that the mAbs are effective against over 95% of all strains and viral subtypes of HIV-1 against which it has been tested. I am not receiving compensation for it (other than from Seeking Alpha). If the company raises capital, it will be able to easily pay its debts: Enzolytics, Inc. has delivered several announcements which may explain the most recent reaction in the stock price. effective against over 95% of all strains and viral subtypes of HIV-1 against which it has been tested. He has litigated over 200 patents in his career. Dec 2014 - Present8 years 6 months. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings stock price. Enzolytics Inc (OTCMKTS: ENZC) is making a dynamic run up the charts emerging as a volume leader in small caps and one of the most exciting stories on the exchange that has attracted legions of new shareholders as it continues northbound with power. He is also the inventor named in several U.S. patents covering technology related to the immunotherapy of HIV and cancer and an immune enhancer based on the IPF (Inactivated Pepsin Fragment) platform. Shareholders are for sure very happy about the stock return delivered. for comprehensive investment analysis. MONROVIA, CA / ACCESSWIRE / January 25, 2017 / Immunotech Laboratories, Inc. (OTC PINK: IMMB - Greymarket) (the"Company" or "IMMB") announced today the completion of successful clinical Phase. Immunotech BG-Europe , under the branded ImmunH , utilizing the technology has successfully completed Phase III clinical trials at the Specialized Hospital for Active Treatment of Infectious and Parasite Disease in Sofia, Bulgaria, specific for the treatment of HIV/AIDS.